Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases.
about
Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safetyDevelopments in Intralesional Therapy for Metastatic MelanomaTreatment options for limited or symptomatic metastatic melanoma.Therapy for unresectable recurrent and in-transit extremity melanoma.Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanomaElectrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma.Current treatment of locoregional recurrence of melanoma.The effect of interleukin-2 on canine peripheral nerve sheath tumours after marginal surgical excision: a double-blind randomized studyTG1042 (Adenovirus-interferon-γ) in primary cutaneous B-cell lymphomas: a phase II clinical trialInduction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapyTargeting the tumor microenvironment to enhance antitumor immune responsesTreatment of in-transit melanoma with intra-lesional interleukin-2: a systematic review.Efficacy of skin-directed therapy for cutaneous metastases from advanced cancer: a meta-analysis.The tumour microenvironment and implications for cancer immunotherapy.Local therapy of cancer with free IL-2.Sentinel lymph node as a target of molecular diagnosis of lymphatic micrometastasis and local immunoresponse to malignant cells.Local immunostimulation leading to rejection of accepted male skin grafts by female mice as a model for cancer immunotherapy.A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma.Velimogene aliplasmid.Intralesional Immunotherapy for Metastatic Melanoma: The Oldest and Newest Treatment in Oncology.Microinvasive melanoma: cutaneous pharmacotherapeutic approaches.Immunotherapy for the management of advanced melanoma: the next steps.Immunomodulation of malignant melanoma by contact sensitizing agents.Intra-lesional interleukin-2 therapy for in transit melanoma.Intralesional therapy for metastatic melanoma.In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf.In situ vaccination for the treatment of cancer.Intralesional immunotherapy as a strategy to treat melanoma.Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma.Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy.Intralesional treatment of metastatic melanoma: a review of therapeutic options.Treatment of cutaneous melanoma: current approaches and future prospects.Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development.Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study.Therapeutic efficacy of Bifidobacterium longum-mediated human interleukin-2 with endostatin or TRAIL in transplanted tumors in mice.Re-inventing intratumoral immunotherapy for melanoma.Limited efficacy of intratumoral IL-2 applied to large melanoma metastases.Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12, tavokinogene telseplasmid).Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma-safety and efficacy in a phase II study.Intratumoral administration of IL2- and TNF-based fusion proteins cures cancer without establishing protective immunity.
P2860
Q24633360-C82CF8D3-8A9F-4E5C-AA09-514A51450907Q28069615-4DE84D51-5CA3-4FCF-B62A-D681D966A698Q31161199-6FE9BCEE-056F-4513-93F9-CAF5B6B3B827Q33348506-25A3E22E-50B5-402B-A20D-F18756A097F6Q33840446-3F719AC6-B4C9-4DAB-9FFC-686CB568C2ABQ34020065-409F2944-3D71-45D0-949F-D77C63430A8DQ34888462-6C0F1EA1-7616-492C-AE04-0AFC8B7D5DB9Q34911120-455E5993-7BEC-45E6-BA12-B1BF951891D0Q35105819-4510DC11-94A5-441C-8F3F-A61B047BA71FQ35119800-7707B535-C241-4F00-9520-F7858BE7EC9CQ35176307-4733506D-5460-47E3-9F13-6E4CEFDF1E18Q35201353-4D9CC427-6324-486A-9B34-12587DB889F4Q35231246-AA767CDA-80FA-4627-8657-768A9C9B138BQ36521830-E73821ED-9A4E-4649-AA91-6252E174C32BQ36585434-67F62077-B74F-4A0C-AA1F-51B52AEB6424Q37028329-33B41901-D5CE-45C3-BFC5-B00255AF261BQ37628065-15999A17-98F9-4460-ACFD-0457F7B89737Q37665688-3A17084A-C184-41D1-8969-800BAB82B9E7Q37724340-A367AA4D-8242-4DD3-94CB-91265069F5D5Q37725792-55DD7413-98AB-4CD2-AB2F-16CB0BD51A67Q38088212-0EAC091F-AB36-47BF-A034-A4E7A4D2A9BCQ38091675-80418D01-BDA6-4DE4-9355-A4C002A69958Q38168949-3C37C46B-37FC-4F01-AB4B-4A6459948058Q38181030-95B0D430-8143-42DC-AE1B-8B18C9950DFBQ38266193-10CB2714-7AFA-4518-9A4C-E94DF97C99D5Q38657642-A2505300-32F6-4293-B7E9-884264C9AA81Q38727470-4EC4CE08-FB19-42E5-BAF6-1804407EFC3DQ38742761-71498734-201C-48D1-9C55-EA432A309F15Q38781322-D12E6F60-876B-4443-A604-1320AA7F16FFQ38988662-B074F552-DA42-44C5-B5F5-0DDD3075AE85Q39081034-4A23FC80-8DA8-413F-9EDC-6F81A237227BQ39801051-364F22DA-B171-426C-83C8-0C9EFF51D341Q39899988-78D164A3-E697-4EE7-90FC-363B539FD3D1Q41740586-7206E451-DCD0-4DF5-BC7F-AB89888F0AEBQ42324447-7B3F5C8E-1118-4210-9502-63C9511E5C25Q44607083-F129D114-B845-4C5B-95EA-06BE50CB6F09Q44853842-05931A8E-5524-41FD-8C73-6C188740CDA3Q45873521-B599EBE2-5173-4116-A581-1A4C5048C6CAQ48891121-347B3C47-81FC-4005-BC02-1CECF77A0CC2Q49687675-8528618B-E47D-4F7E-BAA9-A48318AEC381
P2860
Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Phase II trial of intralesiona ...... ft-tissue melanoma metastases.
@ast
Phase II trial of intralesiona ...... ft-tissue melanoma metastases.
@en
type
label
Phase II trial of intralesiona ...... ft-tissue melanoma metastases.
@ast
Phase II trial of intralesiona ...... ft-tissue melanoma metastases.
@en
prefLabel
Phase II trial of intralesiona ...... ft-tissue melanoma metastases.
@ast
Phase II trial of intralesiona ...... ft-tissue melanoma metastases.
@en
P2093
P2860
P356
P1476
Phase II trial of intralesiona ...... ft-tissue melanoma metastases.
@en
P2093
C Schlegel
T K Eigentler
U M Caroli
P2860
P2888
P304
P356
10.1038/SJ.BJC.6601320
P407
P577
2003-11-01T00:00:00Z
P5875
P6179
1002850974